drug · antibody
ranibizumab biosimilar
Phase 3updated 3mo agoby Lupin Ltd🔗 ChEMBL
Phase 3community read0 votes
🐶 often sniffed alongside
top 8- tagApproval16 co-mentions · 8 sources
- drugBYOOVIZ16 co-mentions · 8 sources
- drugranibizumab13 co-mentions · 13 sources
- drugranibizumab SR13 co-mentions · 13 sources
- companySamsung Bioepis Co Ltd8 co-mentions · 8 sources
- companyXbrane Biopharma AB5 co-mentions · 5 sources
- tagOphthalmology5 co-mentions · 5 sources
- tagBiosimilar5 co-mentions · 5 sources
Antibody drug with a maximum clinical stage of Approval (across all indications), with 9 approved and 26 investigational indications.
indications
indications
Diabetic Macular Edema
targets
Vascular endothelial growth factor A, long form
all catalysts(5)
filing · 5
Apr 30, 2026
filing
Xbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))
ranibizumab biosimilar
→
Apr 30, 2026
filing
Xbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))
ranibizumab biosimilar
→
Apr 30, 2026
filing
Xbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))
ranibizumab biosimilar
→
Apr 30, 2026
filing
Xbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))
ranibizumab biosimilar
→
Apr 30, 2026
filing
Xbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))
ranibizumab biosimilar
→
Trials studying ranibizumab biosimilar
News(1)
- Webinar: From Clinical to Commercial: Talent Strategies for Biopharma GrowthThis webinar provides an assessment of recent job market activity across biopharma and explores how companies approaching commercial readiness or building out sales and marketing teams can navigate…biospace · 23d ago
Data sources
last refreshed 16m ago
Found something off?
comments(0)
5-min edit window · permanent after that